Pharmacokinetics of intravenously administered azithromycin in pediatric patients

Pediatric Infectious Disease Journal

Volumn 24, Issue 1, 2005, Pages 34-39

  Jacobs, Richard F ^a,e   Maples, Holly D ^a,e   Aranda, Jacob V ^b,e   Espinoza, Gabriela M ^c   Knirsch, Charles ^c   Chandra, Richa ^c   Fisher, Jeannine M ^c   Kearns, Gregory L ^d,e  

^a ARKANSAS CHILDREN S HOSPITAL   (United States)

^b CHILDREN'S HOSPITAL OF MICHIGAN   (United States)

^c PFIZER INC   (United States)

^d CHILDREN S MERCY HOSPITAL   (United States)

^e EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH AND HUMAN DEVELOPMENT   (United States)

Author keywords

Azithromycin; Children; Pharmacokinetics

Indexed keywords

AZITHROMYCIN; ANTIINFECTIVE AGENT;

ABDOMINAL PAIN; ADOLESCENT; ANTIBIOTIC THERAPY; AREA UNDER THE CURVE; ARTICLE; BACTERIAL INFECTION; CHILD; CLINICAL TRIAL; DIARRHEA; DRUG BLOOD LEVEL; DRUG HALF LIFE; ERYTHEMA; FEMALE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; INFANT; INJECTION PAIN; INJECTION SITE REACTION; IRRITABILITY; LEUKOPENIA; MAJOR CLINICAL STUDY; MALE; MASS SPECTROMETRY; MULTICENTER STUDY; NAUSEA; OPEN STUDY; PHLEBITIS; PRIORITY JOURNAL; SINGLE DRUG DOSE; AGING; INTRAVENOUS DRUG ADMINISTRATION; PRESCHOOL CHILD;

ADOLESCENT; AGING; ANTI-BACTERIAL AGENTS; AREA UNDER CURVE; AZITHROMYCIN; CHILD; CHILD, PRESCHOOL; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; FEMALE; HUMANS; INFANT; INFUSIONS, INTRAVENOUS; MALE; MASS SPECTROMETRY;

EID: 13944262200     PISSN: 08913668     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.inf.0000148927.48680.fc     Document Type: Article

References (24)

1. Hoban D, Felmingham D. PROTECKT surveillance study: antimicrobial susceptibility of Haemophilus influenzae and Moraxella catarrhalis from community-acquired respiratory tract infections. J Antimicrob Chemother. 2002;50(suppl S1):49-59.
2. Felmingham D, Reinert RR, Hirakata Y, Rodloff A. Increasing prevalence of antimicrobial resistance among isolates of Streptococcus pneumoniae from the PROTEKT surveillance study, and comparative in vitro activity of the ketolide, telithromycin. J Antimicrob Chemother. 2002; 50(suppl 1):25-37.
3. Canton R, Loza E, Morosini MI, Baquero F. Antimicrobial resistance amongst isolates of Streptococcus pyogenes and Staphylococcus aureus in the PROTECKT antimicrobial surveillance programme during 1999-2000. J Antimicrob Chemother. 2002;50(suppl 1):9-24.
4. Gordon KA, Fusco J, Biedenbach DJ, Pfaller MA, Jones RN. Antimicrobial susceptibility testing of clinical isolates of Bordetella pertussis from Northern California: report from the SENTRY Antimicrobial Surveillance Program. Antimicrob Agents Chemother. 2001;45: 3599-3600.
5. Critchley IA, Jones ME, Heinze PD, et al. In vitro activity of levofloxacin against contemporary clinical isolates of Legionella pneumophila, Mycoplasma pneumoniae, and Chlamydia pneumonias from North America and Europe. Clin Microbiol Infect. 2002;8:214-221.
6. Foulds G, Johnson RB. Selection of dose regimens of azithromycin. J Antimicrob Chemother. 1993;31(suppl E):39-50.
7. Baldwin DR, Wise R, Andrews JM, Ashby JP, Honeybourne D. Azithromycin concentrations at the sites of pulmonary infection. Eur Respir J. 1990;3:886-890.
8. Data on file. New York, NY: Pfizer, Inc.
9. Fouda HG, Schneider R. Quantitative determination of the antibiotic azithromycin in human serum by HPLC/MS. In 40th ASMS Conference on Mass Spectrometry and Allied Topics, May 1992, Washington, DC. Washington, DC: American Society of Mass Spectrometry; 1992; 918-919.
10. Arrieta A, Arguedas A, Fernandez P, et al. High-dose azithromycin versus high-dose amoxicillin-clavulanate for treatment of children with recurrent or persistent acute otitis media. Antimicrob Agents Chemother. 2003;47:3179-3186.
11. Harris JS, Kolokathis A, Campbell M, et al. Safety and efficacy of azithromycin in the treatment of community-acquired pneumonia in children. Pediatr Infect Dis J. 1998;17:865-871.
12. Kogan R, Martinez MA, Rubilar L, et al. Comparative randomized trial of azithromycin versus erythromycin and amoxicillin for treatment of community-acquired pneumonia in children. Pediatr Pulmonol. 2003; 35:91-98.
13. Lalak NJ, Morris DL. Azithromycin clinical pharmacokinetics. Clin Pharmacokinet. 1993;25:370-374.
14. Langtry HD, Balfour JA. Azithromycin: a review of its pharmacology and clinical efficacy in the treatment of paediatric infectious diseases. Drugs. 1998;56:273-297.
15. Keams GL, Abdel-Rahman SM, Alander SW, Blowey DL, Leeder JS. Developmental pharmacology: drug disposition, action and therapy in infants and children. N Engl J Med. 2003;349:1157-1167.
16. Nahata MC. Pharmacokinetics of azithromycin in pediatric patients with acute otitis media. Antimicrob Agents Chemother. 1995;39:1875-1877.
17. Stevens RC, Reed MD, Shenep JL, et al. Pharmacokinetics of azithromycin after single- and multiple-doses in children. Pharmacotherapy. 1997;17:874-880.
18. Kitamura K, Kamiya H, Nakano T, Sakurai M. Pharmacokinetic and clinical evaluation of azithromycin in the pediatric field [in Japanese]. Jpn J Antibiot. 1997;50:206-214.
19. Garey KW, Amsden GW. Intravenous azithromycin. Ann Pharmacother. 1999;33:218-228.
20. Luke DR, Foulds G, Cohen SF, Levy B. Safety, toleration, and pharmacokinetics of intravenous azithromycin. Antimicrob Agents Chemother. 1996;6:2577-2581.
21. Chiu LM, Menhinick AM, Johnson PW, Amsden GW. Pharmacokinetics of intravenous azithromycin and ceftriaxone when administered alone and concurrently to healthy volunteers. J Antimicrob Chemother. 2002;50:1075-1079.
22. Gordon EM, Blumer JL. Rationale for single and high dose treatment regimens with azithromycin. Pediatr Infect Dis J. 2004;23:S102-S107.
23. Craig WA. Post antibiotic effects and the dosing of macrolides, azalides and streptogramins. In: Zinner SH, Yound LS, Acar JR, et al., eds. Expanding Indications for the New Macrolides, Azalides, and Streptogranins. New York, NY: Marcel Dekker; 1997:27-38.
24. Rothermel CD. Single-dose azithromycin for acute otitis media: a pharmacokinetic/pharmacodynamic rationale. Curr Ther Res. 2003; 64(suppl A):A4-A15.